{
    "root": "14bf5106-3b8c-4375-8466-c158c8f8f614",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "METFORMIN HYDROCHLORIDE",
    "value": "20250310",
    "ingredients": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6802"
        }
    ],
    "indications": {
        "text": "metformin hydrochloride extended-release tablet biguanide indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . ( 1 )",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "starting dose : 500 mg orally daily evening meal ( 2.1 ) increase dose increments 500 mg every 1 2 weeks , maximum 2,000 mg daily evening meal . ( 2.1 ) patients receiving metformin hydrochloride ( hcl ) tablets may switched metformin hydrochloride extended-release tablets daily total daily dose , 2,000 mg daily . ( 2.1 ) swallow metformin hydrochloride extended-release tablets whole never crush , cut chew . ( 2.1 ) renal impairment : prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) ( 2.2 ) . patients egfr 30 ml/minute/1.73 2 . initiation recommended patients egfr 30 45 ml/minute/1.73 2 . assess risk/benefit continuing metformin hydrochloride egfr falls 45 ml/minute/1.73 2 . discontinue egfr falls 30 ml/minute/1.73 2 . discontinuation iodinated contrast imaging procedures : metformin hydrochloride extended-release tablets may need discontinued time , prior , iodinated contrast imaging procedures ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "metformin hydrochloride extended-release tablets usp , 500 mg available white off-white , oval shaped , biconvex coated tablet , debossed `` l41 `` one side `` lu `` side . metformin hydrochloride extended-release tablets usp , 1,000 mg available white off-white , oval shaped , biconvex coated tablet , debossed `` l42 `` one side `` lu `` side . supplied follows : strength package ndc code 500 mg bottles 100 68180-338-01 1,000 mg bottles 90 68180-339-09 store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) ; [ usp controlled room temperature ] .",
    "adverseReactions": "severe renal impairment : ( egfr 30ml/minute/1.73 2 ) ( 4 , 5.1 ) known hypersensitivity metformin ( 4 ) acute chronic metabolic acidosis , including diabetic ketoacidosis , without coma ( 4 )",
    "indications_original": "Metformin hydrochloride extended-release tablet is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )",
    "contraindications_original": "Starting dose: 500 mg orally once daily with the evening      meal ( 2.1 ) Increase the dose in increments of 500 mg every 1 to 2      weeks, up to a maximum of 2,000 mg once daily with the evening meal.      ( 2.1 ) Patients receiving metformin hydrochloride (HCl) tablets      may be switched to metformin hydrochloride extended-release tablets once      daily at the same total daily dose, up to 2,000 mg once daily.      ( 2.1 ) Swallow metformin hydrochloride extended-release tablets      whole and never crush, cut or chew. ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ). Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 . Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 . Assess risk/benefit of continuing metformin hydrochloride if eGFR falls below 45 mL/minute/1.73 m 2 . Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 . Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride      extended-release tablets may need to be discontinued at time of, or prior      to, iodinated contrast imaging procedures ( 2.3 )",
    "warningsAndPrecautions_original": "Metformin hydrochloride extended-release tablets USP, 500 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with \"L41\" on one side and \"LU\" on the other side.\n                  Metformin hydrochloride extended-release tablets USP, 1,000 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with \"L42\" on one side and \"LU\" on the other side.\n                  They are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                               Strength\n                              \n                           \n                           \n                               Package\n                              \n                           \n                           \n                               NDC Code\n                              \n                           \n                        \n                        \n                            500 mg\n                           \n                            Bottles of 100\n                           \n                            68180-338-01\n                           \n                        \n                        \n                            1,000 mg\n                           \n                            Bottles of 90\n                           \n                            68180-339-09\n                           \n                        \n                     \n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F); [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Severe renal impairment: (eGFR below 30mL/minute/1.73 m 2 ) ( 4 , 5.1 ) Known hypersensitivity to metformin ( 4 ) Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma ( 4 )",
    "drug": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6802"
        }
    ]
}